Read more about how the MIA team continues to play a leading role in advancing the frontiers of melanoma research, presenting new findings at major international oncology conferences - the AACR Annual Meeting in San Diego, the EADO Congress in Prague, and ASCO in Chicago.
Roadmap Workstreams have been meeting regularly to discuss and define key elements of a potential screening program design and evaluate available evidence. Read the latest update on progress to date.
The Roadmap Annual Collaborators Meeting was hosted by MIA on 27 March 2026. Read more and view the Summary Report of the meeting.
Neoadjuvant immunotherapy continues to transform outcomes for people with melanoma and other cancers. Two recent papers show that assessing pathological response after neoadjuvant immunotherapy can be both more efficient and more consistent, without compromising accuracy.
See all the photos from our Melanoma March 2026 events, and download yours.
Inspired by the work of Melanoma Institute Australia, Helen Godwin decided to support MIA through a bequest in her will. Her family recently visited MIA’s Translational Research Laboratory at Charles Perkins Centre (University of Sydney) and heard first-hand how Helen’s generosity will help support melanoma research projects, and ensure her legacy will make a lasting difference.
Karen Smith is a Senior Clinical Data Manager at Melanoma Institute Australia (MIA), based at Westmead Hospital. Read on to learn what it means to be a clinical data manager, Karen's career journey and more!
Should the targeted screening program focus just on melanoma or on all skin cancers? The Roadmap members, including the Consumer and Community Advisory Committee, have reached agreement that the proposed screening program should focus on melanoma.
Carina Paola Cornejo Páramo, who has a PhD in Bioinformatics, works as a Computational Data Scientist in the MIA Personalised Immunotherapy Platform team.
Melanoma March events are held across Australia during March to raise awareness about melanoma and support our life-saving melanoma research, which is also impacting other cancers.
